EADV Congress 2026: Day 3 Recap—5 Headlines to Know

The third day of the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, delivered new long-term efficacy data, pregnancy safety findings, and expert perspectives across psoriasis, cutaneous lupus erythematosus, and atopic dermatitis.

Highlights included 2-year data for an oral interleukin (IL)-23 receptor-blocking peptide at hard-to-treat psoriasis sites, 52-week results for a novel antibody in refractory cutaneous lupus, final findings from a 7-year dupilumab pregnancy registry, and 2 conversations with Leon Kircik, MD, on an investigational oral agent and the broader atopic dermatitis landscape.

1. ICONIC-TOTAL: Icotrokinra Sustains High-Impact Site Clearance at 2 Years

Once-daily oral icotrokinra maintained clearance through Week 112 in plaque psoriasis involving the scalp, genitals, hands and feet, and nails, according to late-breaking results from the phase 3 ICONIC-TOTAL trial. Among patients randomized to icotrokinra, 70% had clear or almost clear skin at Week 112, and complete clearance rates at that point reached 60% for scalp, 89% for genital, and 63% for hand and foot disease. Nail severity improved by 71%, and exposure-adjusted adverse event rates did not rise with longer treatment.

2. AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

Victoria Werth, MD, of the University of Pennsylvania, discussed 52-week data from AMETHYST Part A, a phase 2 study of subcutaneous litifilimab in cutaneous lupus erythematosus refractory or intolerant to antimalarials. Among patients who started the drug during the double-blind period, CLASI-50 response rose from 40.8% at Week 24 to 46.0% at Week 52, and patients who crossed over from placebo began responding within about 4 weeks. Werth emphasized the significance of a potential new option in a disease with no new approved therapies in more than 80 years.

3. No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH

Final results from a prospective pregnancy registry run from 2018 to 2025 found no evidence of increased risk for major structural birth defects with dupilumab exposure, according to Christina Chambers, PhD, MPH, of UC San Diego. Compared with women who had the same underlying conditions but no dupilumab exposure, the weighted relative risk was 0.77 (95% CI, 0.40-1.50) among 539 enrolled participants. Chambers noted the registry finished recruitment in 5 years, far faster than the decade or more pregnancy safety data often require.

4. First-in-Class Oral ENV-294 Evaluated in Atopic Dermatitis, With Leon Kircik, MD

Kircik discussed phase 1b open-label data for ENV-294, an investigational oral Rac2 modulator, in 9 patients with moderate to severe atopic dermatitis. After 28 days of monotherapy, EASI scores fell by 68%, and the reduction deepened to 85% at day 42, 2 weeks after treatment ended. The only adverse event was a single mild headache. Kircik urged cautious optimism given the small sample, noting a placebo-controlled phase 2 trial is enrolling.

5. Oral Options, TYK2 Inhibitors, and Atopic Dermatitis Innovations, With Leon Kircik, MD

In a second segment of his interview, Kircik stepped back to look at the broader atopic dermatitis field, identifying oral therapies as a key unmet need, particularly for children averse to injections. He described the pace of innovation as much faster than psoriasis experienced during its early biologic era. Among emerging agents, he highlighted newer TYK2 inhibitors and rezpegaldesleukin, a first-in-class agent acting on the IL-2 receptor complex now also being studied in alopecia areata.